Janus innecto4/2/2023 ![]() ![]() ![]() IBD JAK inhibitors future perspectives phase I and II clinical trials. Janus, in Roman religion, the animistic spirit of doorways (januae) and archways (jani). According to some, he was the custodian of the universe but, to all Romans, he was the god of the beginnings and the ends, presiding over every entrance and departure, and because every door and passageway looks in two directions, Janus was seen as two-faced or Janus bifrons the god who looked both ways. In the next years, the approach to patients with IBD will become increasingly personalized. For that reason the JANUS developing process has been, since the beginning, as inclusive as possible, involving academia, industry and governmental agencies, and subject matter experts in. JAK inhibitors, if approved by the regulatory authorities, could represent a novel and intriguing drug class. Doorkeeper of the heavens In Roman mythology, Janus was a king of Latium (a region of central Italy), who had his palace on the Janiculum hill, on the western bank of the River Tiber. Adopted globally, JANUS is aimed at stopping the current underwater Tower of Babel between modems and systems of different manufacturers and nations. ![]() This review describes the JAK-STAT pathway and analyzes the efficacy and safety of new small molecules such as filgotinib, upadacitinib, TD-1473, peficitinib, and Pf-06651600/Pf-06700841, showing data from phase I and II trials. The aim of this review is to provide an overview of the JAK inhibitors currently under investigation in phase I and II clinical trials for patients with Crohn's disease and ulcerative colitis and the possible future perspectives for the treatment of IBD patients with this class of drugs. A new pharmacological class, Janus kinases (JAK) inhibitors, has been shown to be effective and safe for the treatment of inflammatory bowel diseases (IBDs). ![]()
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |